Aadi Bioscience to be Acquired for $100M

Ticker: WHWK · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1422142

Sentiment: bullish

Topics: acquisition, merger, cash-deal

TL;DR

Aadi Bioscience is being bought out for $100M cash, deal expected Q4 2024.

AI Summary

Aadi Bioscience, Inc. reported on August 16, 2024, that it has entered into a definitive agreement to be acquired by Anria Acquisition Corp., a wholly-owned subsidiary of Anria Holdings, Inc. The transaction is valued at approximately $10.00 per share in cash, representing a total equity value of approximately $100 million. This acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by Anria Holdings, Inc. signifies a significant financial event for Aadi Bioscience shareholders, providing them with a cash payout and potentially impacting the future development of Aadi's pipeline.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of the deal falling through or changes in terms.

Key Numbers

Key Players & Entities

FAQ

What is the total value of the acquisition agreement?

The acquisition is valued at approximately $100 million in total equity value.

What is the price per share being offered?

The offer is $10.00 per share in cash.

Who is acquiring Aadi Bioscience?

Aadi Bioscience is being acquired by Anria Acquisition Corp., a subsidiary of Anria Holdings, Inc.

When is the acquisition expected to close?

The transaction is expected to close in the fourth quarter of 2024.

What are the conditions for the acquisition to close?

The acquisition is subject to customary closing conditions.

Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-08-20 21:21:59

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated August 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 20, 2024 /s/ Scott Giacobello Scott Giacobello Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing